Weight Control at WeightControl.com

Cleveland Clinic Study Evaluates Weight Changes after Discontinuation of Semaglutide or Tirzepatide

Among patients who started the treatment for obesity, the average weight change from baseline to discontinuation was -7.1% with semaglutide and -12.2 with tirzepatide.

WeightControl.com Interview with:
Hamlet Gasoyan, DS, PhD, MPH
Staff, Internal Medicine
Investigator, Center for Value-Based Care Research
Assistant Professor of Medicine,
Cleveland Clinic Lerner College of Medicine of Case Western Reserve
Cleveland, OH

WeightControl.com: What is the background for this study?

Response: Despite the popularity of semaglutide and tirzepatide for obesity, discontinuation rates of these medications at 1-year range from 47% to 65%. Limited data are available about what additional weight management efforts patients pursue in real-world settings after discontinuing semaglutide or tirzepatide, and whether long-term weight changes after discontinuation follow the patterns reported in randomized clinical trials.

Weight Control Meds May Influence Not Just How Much People Eat but What they Eat

Using supermarket purchase data, we found that individuals initiating GLP-1 RA treatment showed small but significant changes in their food purchases.

WeightControl.com Interview with:
Kathrine Kold Sørensen, postdoc, PhD, cand.scient.san.publ
Copenhagen University Hospital – Steno Diabetes Center Copenhagen
Department for Clinical and Translational Research
Denmark

WeightControl.com: What is the background for this study?

Response: GLP-1 receptor agonists are widely used in the treatment of type 2 diabetes and obesity and are known to improve weight and metabolic outcomes. Beyond weight loss, however, the mechanisms underlying these benefits are not fully understood. Smaller studies and case reports have suggested that GLP-1 RAs may influence food preferences.

Pages: 12